Hsia J et al. J Am Coll Cardiol 2011;57:1666-75

Baseline Characteristics by Treatment Group and Attained LDL-C

Hsia J et al. J Am Coll Cardiol 2011;57:1666-75

Independent Predictors of Attaining LDL-C <50 mg/dl at Any Visit Among

Rosuvastatin-Allocated Patients

Hsia J et al. J Am Coll Cardiol 2011;57:1666-75

Cardiovascular Events and All-Cause Mortality by Baseline LDL-C Level

Hsia J et al. J Am Coll Cardiol 2011;57:1666-75

Time to Occurrence of Major Cardiovascular Events According to Treatment Group and Achieved LDL-C Concentrations

Hsia J et al. J Am Coll Cardiol 2011;57:1666-75

Primary Endpoint in Pre-Specified Subgroups Within JUPITER Trial, Stratified by Achieved LDL-C

Hsi

a J

et a

l. J

Am

Col

l Car

diol

201

1;57

:166

6-75

Fully-Adjusted Hazard Ratios for Incident Cardiovascular Events and All-Cause Mortality According to Treatment

Group and Achieved Concentrations of LDL-C

Hsia J et al. J Am Coll Cardiol 2011;57:1666-75

Numbers and Rates (per 100 Person-Years) of Treatment-Emergent Adverse Events by Treatment Group and Attained LDL-C

Hsia J et al. J Am Coll Cardiol 2011;57:1666-75

ALT or CK Elevation, Proteinuria, or Hematuria at Any Follow-Up Visit by Treatment Assignment and Attained LDL-C

Hsia J et al. J Am Coll Cardiol 2011;57:1666-75

Relation of Major Cardiovascular Event Rate to LDL-C at 1 Year in Primary Prevention Trials

Hsia J et al. J Am Coll Cardiol 2011;57:1666-75